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Abstract
We aimed to determine if increased non-enzymatic glycosylation of the LDL was sufficient to increase the susceptibility to in vivo
oxidation of the LDL particles. Twenty-two type 2 diabetic patients (11 males and 11 females) were included in this study. They were enrolled
on the basis of good [glycated hemoglobin (HbA1c) < 7%] and poor glycemic control [(HbA1c) > 8%]. LDL were isolated by sequential
ultracentrifugation and analyzed by capillary electrophoresis (CE) for diene conjugate content and for electronegativity. The glyc-LDL levels
were increased in all diabetic type 2 patients, peaking in the diabetic subjects in poor diabetic control (17.3 ± 8.07%). The LDL content of
diene conjugates was similar between the two groups (6.65 ± 0.77% for the patients with good glycemic control versus 6.88 ± 0.74% for
those with poor glycemic control; P = 0.49) as was the electrophoretic mobility ((−1.14544± 0.089)× 10−4 cm2/(V s) for the patients with
good glycemic control and (−1.13666± 0.073)× 10−4 cm2/(V s) for those with poor glycemic control; P = 0.80).
The susceptibility to in vivo oxidation of LDL from type 2 diabetic patients in poor glycemic control did not differ from that of well-controlled
diabetic patients. LDL glycosylation was not able to increase the oxidizability of LDL in the diabetic patients with poor glycemic control.
© 2003 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The increased atherogenic risk associated with dia-
betes is accentuated by the numerous differences described
between lipoproteins from diabetic and non-diabetic in-
dividuals [1,2]. Because of hyperglycemia most plasma
apolipoproteins from diabetic subjects become glycosylated
and impaired in their biological function [3]. Glycosylation
is a process that increases the negative charge of LDL [4].
Modifications that increase the net negative charge may
have important metabolic consequences and enhance LDL
atherogenicity [5,6]. Glycated LDL (glyc-LDL) is catabo-
lized more slowly than normal LDL [7,8], and is degraded
by the scavenger pathway promoting foam cell formation
[9]. The advanced glycation end-products (AGE) process
is one of the main pathogenic mechanisms linked to the
development of diabetic complications [10]. AGE may
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arise via several mechanisms. In non-oxidative pathway,
AGE can be produced by reaction of reducing sugars with
protein amino groups throughout the cascade of Maillard
reaction. The oxidative pathway of AGE formation involves
the participation of reactive oxygen species producing
glyco-oxidative products [10]. Increased oxidative-stress
probably contributes to the increased susceptibility to ox-
idation [11]. An increase in AGE accumulation precedes
the histological evidence of diabetic microvascular damage.
Type 2 diabetes complications primarily affect the vascu-
lar system, leading to diabetic microangiopathy and to an
accelerated development of atherosclerosis [12].
The electrophoretic mobility is one of the more reliable
indicators of LDL modification. Conventionally, changes in
the electrophoretic mobility of LDL particles were deter-
mined in agarose gel using a barbital buffer, or in capillary
electrophoresis (CE) [13].
It has been reported that in type 2 diabetes the majority
of LDLs are small and dense, especially at high triglyceride
levels. Small dense LDL particles are triglyceride-enriched
lighter particles that reside in slow turnover metabolic
pool [14]. It was found that small dense LDLs are more
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susceptible to oxidation [15]. To determine the suscepti-
bility of LDL to in vivo oxidation we have applied the
measure of the amount of baseline diene conjugation (BDC)
in LDL [16], which is a clinically applicable method to
estimate in vivo LDL oxidation. Strong correlation between
the titer of autoantibodies against oxidized LDL and results
of high performance liquid chromatography (HPLC) and
nuclear magnetic resonance (NMR) studies indicated that
BDC-LDL was a specific measure of oxidized LDL in vivo
[16,17].
The present study examined the proportion of circulating
glycated LDL in type 2 diabetic patients and the LDL sus-
ceptibility to oxidation through the precise measurement of
the electrophoretic mobility by capillary electrophoresis and
the UV absorption at 234 nm that results from the formation
of conjugated dienes in constituent polyenoic fatty acids.
2. Subjects and methods
2.1. Study subjects
Twenty-two type 2 diabetic patients (11 males and 11 fe-
males) were included in this study. They were recruited from
the diabetes clinic at the San Giovanni Battista Hospital in
Turin (Italy). They were enrolled on the basis of good [gly-
cated hemoglobin(HbA1c) < 7%] and poor glycemic con-
trol [(HbA1c) > 8%]. Diabetes was defined according to
the National Diabetes Data Group criteria [18]. For the dia-
betic subjects in good glycemic control mean age was 67±9
years, body mass index (BMI) was 29±5 kg/m2, and known
diabetes duration was 8± 8 years. For the diabetic subjects
in poor glycemic control mean age was 63±12 years, body
mass index (BMI) was 31 ± 3 kg/m2, and known diabetes
duration was 12 ± 5 years. Anthropometric characteristics,
glycemic control parameters, and lipid profiles of type 2 di-
abetic patients are shown in Table 1.
All the patients were on hypoglycemic oral agents and
none of the patients was taking drugs or vitamins, or had
any disease known to influence lipoprotein metabolism.
Table 1
Anthropometric characteristics, glycemic control parameters, and lipid







Sex (M/F) 6/5 6/5
Age (year) 67 ± 9 63 ± 12
Diabetes duration (year) 8 ± 8 12 ± 5
BMI (kg/m2) 29 ± 5 31 ± 3
HbA1c (%) 6.4 ± 0.58∗∗ 10.2 ± 0.9
Glucose (mg/dl) 136 ± 43∗∗ 195 ± 53
Cholesterol (mg/dl) 215 ± 48 201 ± 48
Triglycerides (mg/dl) 146 ± 44 166 ± 55
LDL cholesterol (mg/dl) 135 ± 49 124 ± 43
HDL cholesterol (mg/dl) 51 ± 15 47 ± 11
∗∗ P < 0.01.
Eleven healthy subjects matched for sex, age, and lipid
profile were recruited as a control group.
Informed consent was obtained from all the enrolled sub-
jects and the reported investigations were carried out in ac-
cordance with the principle of the Declaration of Helsinki
[19].
2.2. Biochemical analyses
Glucose was determined by a standardized automatized
enzymatic method (glucose oxidase) (Alfa Wassermann, Mi-
lan, Italy) adapted to a Schimadzu CL 7000 autoanalyzer.
Cholesterol and triglyceride concentrations were determined
from plasma and lipoprotein fraction by enzymatic methods
(Alfa Wassermann, Milan, Italy) in a Schimadzu CL7000
autoanalyzer.
2.3. Isolation of LDL
Venous blood was collected from all participants into
EDTA-containing Vacutainer tubes, and plasma was sepa-
rated by low-speed centrifugation for 15 min at 4 ◦C. LDL
was isolated by preparative sequential ultracentrifugation
[20] in a Beckman L8-70M ultracentrifuge (Beckman Instru-
ments Inc.). Plasma was adjusted to d = 1.019 g/ml with
KBr solution and ultracentrifuged at 42 000 rpm (121 000 g)
for 20 h at 18 ◦C in a Beckman 70.1 Rotor. After centrifu-
gation, the very low density lipoprotein (VLDL) fraction
was removed by the tube slicing and the infranate was ad-
justed to d = 1.063 g/ml and ultracentrifuged at 46 000 rpm
(148 000 g) for 21 h at 18 ◦C. To avoid oxidative modifica-
tion of lipoproteins 1 mmol/l EDTA was added to all KBr
solutions in the two sequential ultracentrifugations. The frac-
tion containing LDL was removed by tube slicing and dia-
lyzed through Sephadex G-25 columns (Pharmacia) against
buffers used in the subsequent experiment.
2.4. Chromatographic assays
HbA1c: HbA1c was routinely determined by standard-
ized affinity high performance liquid chromatography (Bio
Rad, Italy). The reference range in our laboratory is 4.0–
5.8%.
Glyc-LDL: Glyc-LDL percentage was evaluated by affin-
ity chromatography using m-amino-phenyl-boronic acid
coupled with agarose (Sigma) as described [21]. Five
milliliters of the resin was packed in a glass column at
a flow of 1 ml/min. The column was connected to a low
pressure chromatography system. The column was equili-
brated with binding buffer (250 mmol/l ammonium acetate,
50 mmol/l MgCl2, 500 mmol/l NaCl, 3 mmol/l NaN3, and
0.1% Tween-20, pH 8.5 at 20 ◦C. An aliquot of LDL was
dialyzed against binding buffer by gel filtration chromatog-
raphy (G25M; Pharmacia) and about 400g of LDL were
injected into the column. Non-glyc-LDL was eluted in the
unbound fraction with 20 ml binding buffer at a flow rate of
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1 ml/min. The glycated LDL fraction was eluted with elution
buffer (200 mmol/l sorbitol, 500 mmol/l NaCl, 50 mmol/l
Na2-EDTA, 100 mmol/l Tris, and 0.1% Tween-20, pH 8.5.
Two peaks of LDL, corresponding to non-glyc-LDL and
glyc-LDL were detected at 254 nm and their peak area were
integrated.
2.5. Capillary electrophoresis
Capillary electrophoresis was performed with a Beck-
man P/ACE 5510 System fitted with a diode array detec-
tor. An untreated fused silica capillary tube with a 75m
i.d. was used. The total length of the capillary tube was
57 cm (50 cm to the detector). The capillary was operated
at 20 ◦C. An applied voltage of 350 V/cm was used in all
CE separations. Capillary electrophoresis was performed as
described by Stock and Miller [13]. The cathode and an-
ode electrolytes and the capillary run buffer were 40 mM
methylglucamine-Tricine, pH 9.0. LDL samples were in-
jected by low pressure for 4 s. Dimethylformamide was in-
jected as an electroendosmotic flow (EOF) marker for 1 s.
A voltage of 24 kV was applied ramping over 0.8 min. Mi-
gration of LDL particle was monitored at 200 and 234 nm.
The amount of conjugated dienes is obtained from the per-
centage of the height of LDL peak at 234 nm related to the
height of LDL peak at 200 nm.
2.6. Calculation of electrophoretic mobility
The electrophoretic mobility of LDL (µ) was calculated
using the following equation [22]: µ = LcLd/U(1/tsample−
1/tEOF) where Lc is the total length of the capillary (cm), Ld
the length of the capillary from injector to detector (cm), U
the applied voltage (V), tsample the migration time of LDL in
seconds, and tEOF is the migration time of the EOF marker
in seconds.
2.7. Statistical analysis
Data were expressed as mean±S.D. unless otherwise in-
dicated. Student’s t-test was used to compare groups when
variables were normally distributed. Pearson’s correlation
coefficients were used to describe relationships between
variables. In all cases, P of a value less than 0.05 was con-
sidered statistically significant.
3. Results
The diabetic patients in good glycemic control had a
HbA1c levels of 6.4 ± 0.58%, and those with poor dia-
betic control had a HbA1c value of 10.2 ± 0.9% (P =
0.000). The fasting glucose concentrations were 136 ± 43
and 195± 53 mg/dl, respectively, (P = 0.009) (Table 1).
As expected, type 2 diabetic patients with poor glycemic
control presented increased proportion (17.3 ± 8.07%) of
Table 2







Glyc-LDL (%) 9.73 ± 4.32∗ 17.3 ± 8.07
Electrophoretic mobility
(× 10−4 cm2/(V s))
−1.14544 ± 0.089 −1.13666 ± 0.073
Diene conjugates (%) 6.65 ± 0.77 6.88 ± 0.74
∗ P < 0.05.
glycated LDL compared with type 2 diabetic subjects with
good glycemic control (9.73± 4.32%; P = 0.01).
The LDL electrophoretic mobility mean for the diabetic
group was (−1.14015± 0.08)× 10−4 cm2/(V s). The elec-
trophoretic mobility of LDL between the two diabetic sub-
groups did not vary ((−1.14544±0.089)×10−4 cm2/(V s)
for the patients with good glycemic control and (−1.13666±
0.073)×10−4 cm2/(V s) for those with poor glycemic con-
trol; P = 0.80) (Table 2). In both diabetic groups, LDL
electrophoretic mobility was significantly higher than that
found in the control group (P < 0.05 control versus both
groups).
The contents in diene conjugates of LDL is 6.76±0.75%
in the whole group and it is higher than the level found
in the control group (5.9 ± 0.3; P = 0.001). No signifi-
cant difference was observed between the diabetics in good
(6.65 ± 0.77%) and poor glycemic control (6.88 ± 0.74%;
P = 0.49) (Table 2).
Table 3 shows the Pearson’s correlation coefficients be-
tween the concentration of glycated LDL and those of
HbA1c, glucose, LDL electrophoretic mobility and content
in diene conjugates, and the correlation coefficients between
diene conjugates and LDL electrophoretic mobility in the
different group of diabetic subjects. Glyc-LDL correlated
positively with HbA1c in the whole group of diabetic sub-
jects (r = 0.65; P = 0.0009). Within the diabetic group this
Table 3
Pearson’s correlation coefficients between serum glycated LDL and
HbA1c, plasma glucose levels, LDL electrophoretic mobility and LDL
diene conjugates content and Pearson’s correlation coefficients between









N 22 11 11
Glyc-LDL vs.
HbA1c 0.65∗∗ −0.16 0.74∗∗








∗ P < 0.05.
∗∗ P < 0.01.
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correlation is kept only in the subjects with poor glycemic
control (r = 0.74; P = 0.009).
Glyc-LDL correlated positively with glucose in the whole
group of diabetic subjects (r = 0.58; P = 0.004), but this
correlation faded away when the statistical analyses was
performed on the two separated groups.
Glyc-LDL correlated positively with electrophoretic mo-
bility in the whole group of diabetic subjects (r = 0.64;
P = 0.001), and in the subjects with poor glycemic control
(r = 0.74; P = 0.008).
Glyc-LDL correlated negatively with the amount of diene
content in the whole group of diabetic subjects (r = −0.66;
P < 0.0006), and in the patients with HbA1c level <7%
(r = −0.76; P = 0.006). The diabetic patients with poor
diabetic control did not present a significant correlation be-
tween glycated LDL and diene conjugated content.
The content in diene conjugates of LDL showed a good
correlation with the electrophoretic mobility both in the
whole group (r = −0.68; P = 0.0005) and in the sub-
groups with good (r = −0.68; P = 0.02) or poor glycemic
control (r = −0.71; P = 0.01). Although this correlation
is expressed with a negative sign, it has in reality a posi-
tive meaning because the electrophoretic mobility of LDL
is usually expressed with a negative value.
4. Discussion
Our study was designed to quantify the fraction of gly-
cosylated LDL in type 2 diabetic patients and to determine
if the susceptibility of LDL to oxidation is altered in type
2 diabetic patients in poor glycemic control. We aimed to
determine if increased non-enzymatic glycosylation of the
LDL was sufficient to increase the susceptibility of the LDL
particles in vivo.
As expected, the glyc-LDL levels were increased in all
diabetic type 2 patients when compared to those of control
subjects (4±0.8%) and the highest concentration was found
in patients in poor glycemic control. Our results of glycated
LDL are far higher than those published by other authors
[23,24]. Moreover, to be sure that no non-specific substances
were bound to the resin, we added Tween-20 as a deter-
gent according to Fless and coworkers [21]. The absorbance
of the peaks was measured at 254 nm and not at 280 nm
as others reported [23], and this wavelength allows greater
sensitivity. Others authors [24] have used an immunoassay
method to quantify the percentage of glycated LDL. So far,
no standard methods for glycated LDL exist and the hetero-
geneity of the employed laboratory methods could explain
these discrepancies.
The susceptibility to in vivo oxidation of LDL from type
2 diabetic patients in poor glycemic control did not differ
from that of well-controlled diabetes. The LDL content of
diene conjugates was similar between the two groups, as was
the electrophoretic mobility was. The increase in absorbance
measured at 234 nm parallels the formation of conjugated
dienes in constituent fatty acids, the production of thiobar-
bituric acid-reacting substances, and the accumulation of
lipid hydroperoxides and cholesterol peroxidation products
[25–27], whereas the measure of the electrophoretic mobil-
ity of LDL is considered an indicator of lipoprotein modi-
fications [28]. An increased electronegativity of LDL is the
result not only of the oxidative damage [25] and the ex-
tent of cholesterol oxidation [29], but also of glycosylation.
Both oxidation and non-enzymatic glycosylation share an
increase in the electronegativity of LDL as a common char-
acteristic [23]. The lack of difference in electrophoretic mo-
bility of LDL observed between the two groups suggests
that the glycosylation of LDL has reached the saturation lev-
els. LDL glycosylation, which reflects the modification of
lipoprotein, accounts for the increased electrophoretic mo-
bility of diabetic LDL compared to that of LDL isolated from
a control group. LDL glycosylation was not able to further
increase the oxidizability of LDL in the diabetic patients in
poor glycemic control. In agreement with that, the negative
correlation found between glycated LDL and diene conju-
gates explains that glycosylation can offer lipoproteins more
resistance to the further oxidation process as other authors
have suggested [30]. We suppose that the similar oxidizabil-
ity observed in LDL of the two diabetic groups is due to
the early phases of the LDL oxidation which are delayed by
glucose as long as the vitamin E content is preserved. LDL
vitamins E content was not different in the diabetic subjects
with good or poor glycemic control (data not shown). How-
ever, we expected the rate of LDL oxidation to speed up
once LDL vitamin E has been consumed as other authors
have reported [31].
The high circulating glucose level accounts for the
non-enzymatic glycosylation of LDL as proved by the sig-
nificant correlation of glyc-LDL with glucose and HbA1c. In
these patients LDL are clearly modified and these modifica-
tions are highlighted by the correlation of the LDL content
in diene conjugates with the LDL electrophoretic mobility
existing both in the whole group (r = −0.68; P = 0.0005)
and in the subgroups with good (r = −0.68; P = 0.02) or
poor glycemic control (r = −0.71; P = 0.01). As expressed
above, despite the negative sign, the correlation has in real-
ity a positive meaning since the electrophoretic mobility of
LDL is usually expressed with a negative value [22].
In addition to the saturation theory, we do not exclude
that the capillary electrophoresis be able to detect modified
LDL due to glycation irrespective of the number of glucose
molecules attached to lipoproteins.
Higher electric charge and enhanced degree of glyca-
tion are physiochemical and biochemical parameters dif-
ferentiating lipoproteins in type 2 diabetic patients from
lipoproteins in non-diabetic individuals. These lipoprotein
modifications can contribute to the increased risk of coro-
nary atherosclerosis (CHD) associated with diabetes [1,2].
These observations led us to agree with other authors [24]
who supposed that glyc-LDL could be used as a sensitive
index of short-to-long term glycemic control in diabetes
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[32,33]. Glyc-LDL measurement could also simultaneous
provide an index of the relative atherogenicity of circulating
LDL, especially as glyc-LDL has a higher content of diene
conjugates and higher electrophoretic mobility than normal
subjects.
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